Novo Nordisk Sees UAE as Key Market
Danish company Novo Nordisk announced the launch of the oral tablet form of the drug "Wegovy" in the UAE market, as part of its global expansion. The medication addresses obesity and its related conditions. The company focused on developing an oral tablet for the peptide Wegovy to enhance patient comfort and expand clinical applications, highlighting its health benefits, including heart and kidney protection, and achieving safety over more than 50 million years of patient lives. The UAE is considered a strategic choice due to its leadership in healthcare, as the company continues to expand its presence following its launch in the United States and Europe.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)